Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 8 (2022) > Article

DOI: 10.14704/nq.2022.20.8.NQ44783

Study of IgG and IgM antibody response afterPfizer mRNA Vaccine first dose in Previously infected with COVID-19and uninfected individuals

Fadhil Kahdim Jassim, Aseel kasim kareem, Maher Mohammed Khadairi,Nassar Abdalaema Mera, MahirAbdulkadhum Alzughaibi, Mohammed Zuhair Naji, Saif Sahib Radhi, Ali Fahim Mohammed, Marowa H Abbas


The current research aimedto demonstrate the extent such as increase in the rate of immune response to antibodies (IgG, IgM) for people who received the first dose of the Pfizer mRNA vaccine at (1-3) weeks times period and to compare them with people who were not taken for the first dose of the same vaccine and none infected with COVID -19.Also the results appearedsignificant variations in immunoglobulin (IgG) levels (P≤ 0.05) between case (Recipients mRNA vaccination) and control patients, there were. In terms of age and gender, however, there were no significant changes (P≥ 0.05) in immunoglobulin (IgM) levels between case (Recipients mRNA vaccination) and control patients


COVID-19, Pfizer mRNA Vaccine ,IgG,IgM.

Full Text